Sugi Predict

Sugi Predict / Compounds / SCHEMBL284484

SCHEMBL284484

SCHEMBL284484

Cc1ccc(S(=O)(=O)N[C@@H](CCCCN)C(=O)C(Cl)C(=O)C(Cl)C(=O)[C@H](CCCCN)NS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 5/20 0.56
▸ MMP9 P14780 3/20 0.56
▸ PLAU P00749 5/20 0.47
▸ HPN P05981 5/20 0.47
▸ TDP1 Q9NUW8 1/20 0.44
▸ SLC1A3 P43003 1/20 0.43
▸ SLC1A2 P43004 1/20 0.43
▸ SLC1A1 P43005 1/20 0.43
▸ ITGB3 P05106 1/20 0.43
▸ ITGA2B P08514 1/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA12 O43570 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ MMP13 P45452 4/20 0.41
▸ MMP1 P03956 2/20 0.41
▸ CA1 P00915 1/20 0.41
▸ MMP8 P22894 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ MMP3 P08254 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1115907 1.00 MMP2 (0.56) MMP2MMP9PLAUHPNTDP1
SCHEMBL284482 0.87 MMP2 (0.53) MMP2MMP9PLAUHPNTDP1
SCHEMBL1421131 0.87 MMP2 (0.53) MMP2MMP9PLAUHPNTDP1
SCHEMBL28509074 0.86 MMP2 (0.60) MMP2MMP9PLAUHPNTDP1
SCHEMBL8965842 0.85 MMP9 (0.65) MMP2MMP9PLAUHPNTDP1
SCHEMBL457772 0.85 MMP9 (0.76) MMP2MMP9PLAUHPNTDP1
SCHEMBL10585071 0.85 MMP9 (0.76) MMP2MMP9PLAUHPNTDP1
SCHEMBL6893970 0.85 MMP2 (0.61) MMP2MMP9PLAUHPNTDP1
SCHEMBL8001084 0.85 MMP9 (0.76) MMP2MMP9PLAUHPNTDP1
SCHEMBL200247 0.84 MMP2 (0.57) MMP2MMP9PLAUHPNTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102695520-A Modulating interstitial pressure and oncolytic viral delivery and distribution ONCOLYTICS BIOTECH INC 2012-09-26 — — CN claimed
US-20230146930-A1 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII MINERVA IMAGING APS (DK) 2023-05-11 — — US disclosed
EP-3402537-B1 QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABELLED ACTIVE SITE INHIBITED FACTOR VII RIGSHOSPITALET (DK) 2021-01-06 — — EP disclosed
US-10577639-B2 Rapid bed-side measurement of neutrophil elastase activity in biological fluids UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2020-03-03 — — US disclosed
EP-3541432-A1 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII Minerva Imaging ApS (DK) 2019-09-25 — — EP disclosed
US-20190015532-A1 QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII MINERVA IMAGING APS (DK) 2019-01-17 — — US disclosed
EP-3402537-A1 QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII Rigshospitalet (DK) 2018-11-21 — — EP disclosed
WO-2018091058-A1 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII RIGSHOSPITALET (DK) 2018-05-24 — — WO disclosed
US-20180000899-A1 MODIFYING MACROPHAGE PHENOTYPE FOR TREATMENT OF DISEASE APELLIS PHARMACEUTICALS, INC. 2018-01-04 — — US disclosed
US-9795655-B2 Modified MT-SP1 proteases that inhibit complement activation CATALYST BIOSCIENCES, INC. (US) 2017-10-24 — — US disclosed
EP-0360840-A1 CYTOLYTIC FACTOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1990-04-04 — — EP disclosed
US-4906571-A Cell surface modification using a novel glycoproteinase of pasteurella haemolytica UNIVERSITY OF GUELPH (CA) 1990-03-06 — — US disclosed
WO-1988007868-A1 CYTOLYTIC FACTOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1988-10-20 — — WO disclosed
US-4762789-A THIOL PROTEINASE THE UNIVERSITY OF CALIFORNIA (US) 1988-08-09 — — US disclosed
WO-1988000236-A1 METHODS AND MATERIALS FOR VANADIUM IMMUNOMODULATION TOMPKINS WAYNE A F (US) 1988-01-14 — — WO disclosed
EP-0182906-A1 HUMAN LEUKOCYTE ELASTASE INHIBITORS PREPARED FROM PYOGENIC BACTERIA AND METHODS FOR THEIR PURIFICATION CORTECH, INC. (US) 1986-06-04 — — EP disclosed
WO-1986000077-A1 HUMAN LEUKOCYTE ELASTASE INHIBITORS PREPARED FROM PYOGENIC BACTERIA AND METHODS FOR THEIR PURIFICATION CORTECH, INC. (US) 1986-01-03 — — WO disclosed
US-4368186-A ETHYLENE OXIDE-PROPYLENE OXIDE BLOCK COPOLYMER AND SPERMICIDE SYNTEX (U.S.A.) INC. (US) 1983-01-11 — — US disclosed
EP-0065385-A2 Methods and compositions for intravaginal contraception SYNTEX (U.S.A.) INC. (US) 1982-11-24 — — EP disclosed
US-4016258-A SYSTEMIC VASODILATION, HYPOTENSION RESEARCH CORPORATION 1977-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190015532-A1 QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII F13B, F7, F13A1 MMP2 113/4885MMP9 123/4885PLAU 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.